


Alnylam Pharmaceuticals

Focused on Developing RNAi Therapeutics

Alnylam is a biopharmaceutical company leading the development of RNA interference (RNAi) therapeutics. The discovery of RNAi has been heralded as a major scientific breakthrough, and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today.

RNAi is a natural mechanism of gene silencing that occurs in organisms ranging from plants to mammals. RNAi therapeutics in development have the potential to treat diverse disease states and help patients in a fundamentally new way.



Investigational RNAi Therapeutics

Active Product Pipeline and Experience to Date


RNAi therapeutics in development by Alnylam are engineered to enable a consistent level of target knockdown. Alnylam's pipeline of investigational RNAi therapeutics is currently focused in four Strategic Therapeutic Areas (STAs): **Genetic Medicines, Cardio-Metabolic Diseases, Infectious Disease, and CNS/Ocular Diseases** - and we are actively exploring other disease areas.



* As of April 2025 across all active programs. Numbers are approximate as many studies are ongoing and several are blinded.

To learn more about Alnylam and our pipeline advancements, please visit [Alnylam.com](https://www.alnylam.com)

Our Pipeline



¹ Out-licensed with milestones and/or royalties
² Partnered, Alnylam-led development with US profit split and milestones/royalties ex-US

³ Partner-led with profit split
⁴ Partnered, Alnylam-led with profit split
⁵ Partner-led with Alnylam option for profit split

Alnylam Clinical Development Pipeline as of February 2025

